Physician profile
Eric Chen
NPI 1841672276
$7,418.64
in general payments reported to CMS, 2019-2025
23 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,403 · 2020: $33.66 · 2021: $1,566 · 2022: $1,666 · 2023: $1,144 · 2024: $362 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302 · Travel and Lodging: $1,121 · Long Term Medical Supply Or Device Loan: $307 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.54 |
| Travel and Lodging | $1,121.09 |
| Long Term Medical Supply Or Device Loan | $307.20 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,435.64 | 2021-2025 | Stealthstation S8 Platform, Strata, Mazor X System |
| Globus Medical, INC. | $2,509.43 | 2019-2023 | Corbel |
| Integra Lifesciences Corporation | $307.20 | 2025 | Integra |
| Depuy Synthes Sales INC. | $230.59 | 2022-2025 | Vivigen Mis Delivery System |
| Stryker Corporation | $171.91 | 2024-2025 | Nico Brainpath, Adherus Autospray Dural Sealant, Duramatrix |
| Emd Serono, INC. | $88.91 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.54 | 2025 | Hyqvia |
| Eisai INC. | $73.96 | 2024-2025 | |
| Argenx US, INC. | $66.12 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Kuros Biosciences USA, INC | $53.00 | 2024 | Magnetos |
| Medtronic USA, INC. | $48.47 | 2019-2020 | |
| Livanova USA, INC. | $46.55 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Vertex Pharmaceuticals Incorporated | $45.59 | 2025 | |
| Springworks Therapeutics, INC. | $41.54 | 2025 | Gomekli |
| Impel Pharmaceuticals LLC | $30.50 | 2025 | Trudhesa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $28.67 | 2025 | |
| Ucb, INC. | $27.82 | 2025 | Nayzilam |
| Teva Pharmaceuticals USA, INC. | $26.55 | 2025 | Austedo Xr |
| Alexion Pharmaceuticals, INC. | $26.32 | 2024 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $22.44 | 2025 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Novartis Pharmaceuticals Corporation | $16.65 | 2025 | |
| Lilly USA, LLC | $15.24 | 2025 | Kisunla, Amyvid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.